Bupropion (BW 323U66) has been considered a dopaminergic antidepressant based on its ability to inhibit the uptake of dopamine (DA) somewhat more selectively than it inhibits uptake of norepinephrine (NE) or serotonin (5-HT). This report describes new evidence that bupropion selectively inhibits firing rates of NE cells in the locus coeruleus (LC) at doses significantly lower than those that inhibit activity of midbrain DA cells or dorsal raphe 5-HT cells. The ICso dose (13 mglkg IP) for inhibition of LC firing produced plasma concentrations !hat were not significantly different from those generated by the EDso in the Porsolt test (10 mglkg IP). The fourfold higher dose needed to inhibit DA cell firing (ICso = 42 mglkg IP) was similar to the dose associated with locomotor stimulation in freely moving rats. Bupropion did not change the firing rates of 5-HT cells in the dorsal raphe nucleus at any dose. In both in vitro and in vivo tests, the metabolite 306U73 (hydroxy bupropion), a weak inhibitor of NE uptake, was approximately equipotent to bupropion with regard to inhibition of LC cells. Another metabolite, 494U73, had no effect on LC firing rates over a wide range of doses. Because of species variation in metabolism, 306U73 was not detected in plasma of rats after IV doses of bupropion that inhibited LC firing. Only trace amounts of 306U73 were detected after bupropion dosing for the Porsolt test. Pretreatment with reserpine markedly depleted catecholamines and reduced (by 30-fold) the potency of bupropion to inhibit LC firing. The effects of clonidine, a direct acting U2 agonist, were not significantly changed by reserpine. Likewise, a reduction in the effect of bupropion on LC firing was observed in vitro after depletion of catecholamines with reserpine or tetrabenazine. These results suggest that bupropion preferentially affects NE neurons in locus coeruleus at doses that are active in animal antidepressant tests. The doses of bupropion required to inhibit DA cell firing were associated with inhibition of DA uptake and behavioral stimulation and were significantly higher than those selectively producing behavioral effects in animal antidepressant tests. The acute electrophysiological actions of bupropion on NE cells require a reserpine sensitive store of NE and occur at doses having activity in antidepressant screening tests. [Neuropsychopharmacology 11:133-141, 1994J KEY WORDS: Antidepressive agents; Dopamine; Electrophysiology; Norepinephrine; Rats Bupropion is a novel antidepressant with an undefIned mechanism of action. Studies have shown that it weakly inhibits the uptake of dopamine in vitro (Ferris et al.
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In animal behavioral studies, bupropion prevents tetrabenazine-induced sedation in mice and stress induced immobility in rats, actions shared with tricy clic antidepressants that inhibit norepinephrine uptake (Porsolt et al. 1979; Soroko and Maxwell 1983) . The ob jective of this study was to examine the acute effects of bupropion and its major metabolites on the fIring rates of monoaminergic neurons in rat brain. The results were then correlated with plasma levels and behavioral actions of the drugs.
METHODS

Animals
Female Sprague-Dawley rats weighing 75 to 100 g (CD strain, Charles River Labs, Raleigh, NC) were used for in vitro electro physiological experiments. Male CD rats weighing 220 to 350 g (Charles River) were used for in vivo experiments. The rats were housed in the light-and temperature-controlled animal facility at Burroughs Wellcome Co. Standard rat chow and water were con tinuously available. At least 5 days were allowed for acclimatization to the animal facility before experiments were conducted.
Drugs and Drug Treatments
Bupropion HCl (BW 323U66), hydroxybupropion (BW (White and Wang 1984; Cox et al. 1988; Bunney et a1. 1973) . Dopamine cells recorded in these experiments had fIring rates of 2 to 9 spikes per second. Stereotaxic coordinates for AI D cells were 2.9 to 3. 4 mm anterior to lambda, 0.5 to 0.9 rom lateral of midline, and approximately 6.5 to 8.3 mm below dura. Coordinates for A9 cells were 2.9 to 3.4 mm anterior to lambda, 1.5 to 2.2 mm lateral to midline, and 6.5 to 8. 3 mm below dura. 
Behavioral Experiments
The antidepressant effects of bupropion were deter mined with the Porsolt test (Porsolt et a1. 1978; Soroko and Maxwell 1983) . Rats were given a IS-minute con ditioning trial (water temperature 25°C) followed by a test trial 24 hours later. Intraperitoneal injections of bupropion were given immediately after the condition ing trial, then at 5 hours and 1 hour before the 5-minute test trial. After the test trial, animals were returned to their home cages.
Other animals were tested for locomotor activity that was measured in open fIeld activity cages using established methods (Cooper et a1. 1980; Soroko and Maxwell 1983) .
Analysis of Bupropion Levels and Major Metabolites
Plasma concentrations of bupropion and 306U73 were determined by HPLC analysis with the method of Cooper et al. (1984) as modifIed by DeVane et al. (1986) .
Several bupropion dosing protocols were used to ob tain plasma levels corresponding to electrophysiologi cal and Porsolt test parameters. For correspondence to the electro physiological experiments, blood was drawn 5 minutes after bolus IV doses in chloral hydrate anesthetized rats. In other rats, blood was drawn 1 hour after the last of the three injections in the Porsolt test.
Concentrations of 306U73 were determined in plasma 5 minutes after IV injections of 306U73.
Determination of Whole Brain Catecholamine Levels
Whole brain catecholamine concentrations were deter mined in rats sacrifIced 24 hours after injection of reser pine (2.5 mg/kg SC). Concentrations of NE, DA, and 5-HT were determined by the HPLC method described in Jones-Humble et a1. (1992) . Briefly, brains were rap idly removed from reserpine-treated and control rats, Figure 1 . Effects of bupropion on firing rates of locus coeruleus neurons recorded from rat brain slices in vitro. Tis sue from untreated control (A) or reserpine-treated (e) rats, or brain slices exposed to tetrabenazine (_), as described in Methods, were exposed to various concentrations of bupro pion (3 to 1000 J.lmoIlL). Each point represents the mean ± standard error of the mean (SEM) of 3 to 6 responses for each concentration of bupropion except at 600 and 1000 J.lmoliL where n = 2.
weighed, and frozen on dry ice. After homogenization and extraction of monoamines, analysis was performed by HPLC with electrochemical detection.
RESULTS
Single-Unit Recording: Locus Coeruleus In Vitro
Firing rates of locus coeruleus neurons in brain slices from control rats were inhibited by an average of 76% with concentrations of bupropion up to 30 �mollL (Fig.   1 ). The IC50 for this effect was 14.5 ± 0.9 �mol/L (n = 6).
The metabolite 306U73 inhibited locus coeruleus fIring by 85% at 100 �mol/L and was slightly more potent, with an IC50 of 9.5 ± 0.4 �mol/L (n = 6). Another metabolite, 494U73, did not affect locus coeruleus fIring rates at concentrations up to 100 �mollL.
Depletion of norepinephrine by tetrabenazine in vitro or by reserpine in vivo had pronounced effects on the ability of bupropion to inhibit locus coeruleus neu ronal fIring (Fig. 1) . In brain slices treated with tetra benazine, bupropion inhibited fIring rate, with an IC50 that exceeded 300 �mol/L (n = 6). In brain slices from reserpinized rats, bupropion inhibited fIring by only 11 %, with an extrapolated IC50 exceeding 8500 �mollL (n = 4). The potency of clonidine in brain slices was not different from control and reserpine-treated rats (ICso = 3 nmollL, n = 3 to 4 cells/group), and 100% in hibition of fIring rate was achieved at 10 nmollL. 
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Single-Unit Recording: Locus Coeruleus In Vivo
In control rats, locus coeruleus fIring rates were in hibited by doses of bupropion ranging from 3 to 25 mg/kg IP (Fig. 2, top) . Maximum inhibition of fning af ter 2S mg/kgIP was 74 ± 8% (n = St08 cells/dose) with an 1050 of 12.6 mg/mg IP. The IDso values of 306U73 and bupropion are 1.4 and 2.7 mg/kg IV, respectively. Each point represents the mean ± SEM of 3 to 8 cells at each cumulative dose.
In another series of experiments, the effects of bu propion on LC fIring rates were examined in control rats and in rats given reserpine 2.5 mg/kg SC 24 hours before recordings. Normal rats (n = 8) had baseline spontaneous fi.ring rates of 29. 6 ± 3. 4 spikes every 10 seconds. The IDso for bupropion was 1.7 ± 0. 5 mg/kg IV, and a maximal effect of 74% inhibition occurred af ter 6 to 12 mg/kg IV (Figure 4, top) . No adverse effects were observed in any control animals.
For reserpinized rats (n = 6), baseline spontane ous fIring rates of locus coeruleus neurons (34.2 ± 3.0 spikes/IO sec) were not signihcantly different from those of control animals. The depletion of monoamines with reserpine resulted in a signifi.cant decrease in the potency of bupropion (Fig. 4, top) . The IDso was in creased by a factor of 3D, to 50.8 ± 11.5 mg/kg IV (p = 494U73 had no effect on A9 cell fi.ring in doses up to 25 mg/kg IV ( Figure 5 ). 306U73, in doses up to 12 mg/kg IV, tended to increase the fIring rates of A9 dopa mine neurons, but this effect was not statistically signihcant (p > 0.05, two-tailed t-test). 
Behavioral Experiments
Figure 2 (bottom) shows the effects of bupropion on swimming activity (Porsolt test) and on locomotor be havior in rats. Bupropion caused a dose-related an tagonism of immobility, with an EDso of 7 mg/kg IP. J06Un On", (m�kg iv) Figure 6 . Relationship between IV doses and plasma levels of 306U73 determined 5 minutes after IV doses of 306U73 in rats. The plasma level of 306U73 determined after the IV ID so dose of 306U73 for inhibition of locus coeruleus firing rate was 2.0 �mol/L. No bupropion was detected in rat plasma after doses of 306U73.
In addition, a dose-related stimulation of locomotor ac tivity was seen after higher doses of bupropion (10 to 50 mg/kg IP). Table 1 shows plasma levels of bupropion in rats given bupropion 10 mg/kg IP (as in the Porsolt test) and in rats given bupropion 2.7 mg/kg IV (the ID50 for inhibi tion of locus coeruleus firing rate). Plasma concentra tions of bupropion were not significantly different be tween the two procedures (3.0 !J.mollL for the Porsolt test versus 2. 3 !J.mollL for the single-unit experiments).
Plasma Levels of Bupropion and Its Metabolites in Various Dosing Schedules
After these doses of bupropion, the plasma concentra tion of the metabolite 306U73 was 0. 4 !J.mollL in the Por salt test and not detectable in blood drawn 5 minutes after IV injection of 2.7 mg/kg, a dose of bupropion that inhibited locus coeruleus firing by 50%.
There were dose-related increases in plasma con centrations of 306U73 5 minutes after increasing IV doses of that compound ( Figure 6 ). The ID50 of 306U73 for inhibition of LC firing (1.4 mg/kg IV) resulted in a plasma concentration of 2.0 !J.mollL, a value more closely associated with its ICso for inhibition of norepi nephrine uptake into rat brain synaptosomes (6.6 ± 3.3 !J.mol/L) than for inhibition of dopamine (23 ± 8 !J.mollL) or serotonin (105 ± 11 !J.moIlL) uptake (Ferris and Cooper 1993) . Table 2 shows the levels of NE, DA, and 5-HT in the brains of a group of rats treated with the dose of reser- Values are in picomole/mg of wet weight. NE = norepinephrine; DOPAC = 3,4 dihydroxyphenylacetic acid; HVA = homovanillic acid; DA = dopamine; 5HIAA = 5-hydroxy indole acetic acid; 5HT = serotonin.
Effects of Reserpine Treatment on Monoamine
Concentrations in Whole Brain
pine used before electrophysiological experiments. Nor epinephrine, dopamine, and serotonin were depleted to 19% , 16%, and 19%, respectively, of control values.
DISCUSSION
The acute effects of bupropion in animal antidepres sant tests were more closely associated with its actions on the fIring rates of nor adrenergic locus coeruleus neu rons than its effect on midbrain dopamine neurons.
Bupropion produced partial inhibition of the activity of dopamine neurons at doses in excess of those that were active in the Porsolt test. The major metabolites of bupropion, 306U73, and 494U73, had no effects on dopamine cell activity at any dose. Additionally, bu propion, 306U73, and 494U73 had no effects on the flring of serotonergic dorsal raphe neurons.
The unexpected electrophysiological effects of the bupropion in the locus coeruleus are at odds with our interpretation of earlier neurochemical studies. Ferris et al. (1981) found that bupropion was nearly twice as potent as an inhibitor of dopamine uptake into striatal synaptosomes than as an inhibitor of norepinephrine uptake into hypothalamic synaptosomes. In rats, bupropion selectively inhibited depletion of dopamine by 6-0HDA, with an ED50 of 43 mg/kg IP. Doses over 100 mg/kg were required to antagonize the depletion of norepinephrine produced by the neurotoxin 6-0HDA (Cooper et al. 1980) , conflrming the relative selectivity of bupropion for the dopamine transporter.
Nevertheless, the dose of bupropion that blocked dopa mine uptake in vivo was far higher than the doses that were effective in animal tests predictive of antidepres sant activity (Porsolt test ED50 = 7 mg/kg IP). Whereas the present results do not exclude a possible role for dopamine in the activity of bupropion in animal an tidepressant screening tests, they do not support the earlier view that bupropion had a predominantly dopaminergic mechanism in rat.
The causes of the acute reduction of fIring rate of
Norepinephrine and Wellbutrin 139 locus coeruleus cells produced by bupropion remain to be determined. With regard to indirect mechanisms, inhibition of norepinephrine uptake cannot account for the effect of bupropion on locus coeruleus flring rates because inhibition of NE uptake occurs in vivo at 10-fold higher doses (see Cooper et al. 1980; Ferris et al. 1981; Ferris and Cooper 1993) . Furthermore, bupropion is unlike amphetamine in that it does not release nor epinephrine or dopamine from synaptosomal prepa rations (Ferris et al. 1981; Ferris and Cooper 1993 (Ferris and Cooper, 1993) , we considered two other pos sibilities.
The formation of an active metabolite was consid ered because the clincial literature has proposed that active metabolites are responsible for the antidepres sant activity of bupropion in humans (Perumal et al. 1986; Martin et al. 1990 ). Both 306U73 and 494U73 dis play antidepressant activity in mice (Martin et al. 1990 ).
In humans, CSF and plasma concentrations of 306U73 and 494U73 are greater than levels of the parent com pound (Perumal et al. 1985; Golden et al. 1988; Ferris and Cooper 1993) . In rat electro physiological tests, how ever, only 306U73 exhibited a signiflcant inhibition of locus coeruleus flring, which was equipotent with bupropion. 494U73 produced minor effects at the highest nonlethal dose by the IV route.
We next considered that inhibition of norepineph rine uptake by the metabolite 306U73 might be related to the acute electrophysiological effects of bupropion in rat. 306U73 selectively inhibits norepinephrine trans port in rat brain (Ferris and Cooper 1993) It is also unlikely that bupropion acted indirectly through another neural system that in turn reduced fIring rates of locus coeruleus neurons. Bupropion, 306U73, and 494U73 are not ligands at other major neu rotransmitter receptors in mouse, rat Ferris and Cooper 1993) , or human brain (Richelson and Nelson 1984; Wander et al. 1986 ). Furthermore, bu
propion inhibits the fIring rates of locus coeruleus neu rons in brain slices, a preparation with severed aff er ent connections.
Another possibility was that bupropion exerted effects on locus coeruleus fi.ring rates through an inter action with intracellular norepinephrine. We addressed this issue using pretreatment with reserpine or tetra NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.2 It is also unlikely that the concentrations of bupropion in humans resulting from these doses would produce any acute dopaminergic effects.
Thus, the available information indicates that bu propion predominantly affects the noradrenergic sys tem in rat brain after acute doses. This interaction is difficult to explain by the traditional mechanisms of ei ther release or inhibition of the uptake of NE. A second significant fInding is that the pharmacological proftle of bupropion differs significantly between humans and rats owing to diff erences in metabolism. In the rat, lit tle or no 306U73 is present after treatment, so that the noradrenergic behavioral and electrophysiological effects of bupropion result from bupropion. In humans, the effects of bupropion may well result from the lar ge concentration of the metabolite 306U73 in human plasma, which acts to inhibit the NE transporter.
Finally, we have investigated only the acute elec trophysiological effects of bupropion and its metabo lites in the present study. In patients, the therapeutic effects of antidepressants are generally observed only after several weeks of continuous dosing (Baldessarini 1990 ). Further studies are in progress to clarify the noradrenergic pharmacology of bupropion after chronic treatment and what role, if any, the brain levels of bupropion and metabolites play in explaining the an tidepressant activity of the drug.
